Severe hepatotoxicity associated with bromfenac sodium.
Subacute hepatitis and liver failure occurred in a 40-yr-old woman following a 1-month course of treatment with the nonsteroidal anti-inflammatory drug bromfenac. Serologies for hepatitis A, B, and C were negative, as were antinuclear antibodies and ceruloplasmin. A transjugular liver biopsy demonstrated submassive hepatic necrosis. The clinical course was complicated by encephalopathy, fluid retention, and spontaneous bacterial peritonitis, prompting consideration for liver transplantation. With supportive measures, jaundice and fluid retention resolved over a 3-month period. We conclude that prolonged use of bromfenac was the etiological agent in this case, and that this drug can cause severe hepatotoxicity resulting in liver failure.
Moses
P L
PL
Department of Medicine, University of Vermont College of Medicine, Burlington 05401, USA.
Schroeder
B
B
Alkhatib
O
O
Ferrentino
N
N
Suppan
T
T
Lidofsky
S D
SD
D000328:Adult; D000700:Analgesics / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001577:Benzophenones / Q000009:adverse effects*; D001969:Bromobenzenes / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced* / Q000473:pathology
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; C053083:bromfenac